Evidence map›Paper›PMID 32757642›Full record

ArticleCirculation. Heart failure2020

Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study.

David M Shavelle, Akshay S Desai, William T Abraham, Robert C Bourge, Nirav Raval, Lisa D Rathman, J Thomas Heywood, Rita A Jermyn, Jamie Pelzel, Orvar T Jonsson and 6 more

2 registry-linked trialsOpen access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 88 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 3 pooled it
18.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02279888 completednot on this map

CardioMEMS HF System Post Approval Study

TypeobservationalSponsorAbbott Medical DevicesRan2015 to 2019Enrolled1,214ConditionsHeart Failure, Left-Sided Heart Failure, Congestive Heart FailureArmsCardioMEMS HF System
NCT07350759 recruitingnot on this mapstarted 2026, after this paper: background citation

An Observational Study to Develop an Algorithm to Predict Decompensation of Congestive Heart Failure (dCHF) Using a Non-Invasive Wearable Device.

Typeobservational_patient_registrySponsorCHFDX,Inc.Ran2026 to 2026Enrolled60ConditionsDecompensated Chronic Heart FailureArmswearable ring device with multiple embedded sensors to detect heart rate, SVO2, respiratory rate, heart rate variability and a number of other related physiologic parameters
3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 3 syntheses or guidelines pooled it, 182 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials.Clinical research in cardiology : official journal of the German Cardiac Society · 2023
    Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Observational
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 15 institutions in 4 countries.

David M ShavelleDivision of Cardiovascular Medicine, University of Southern California, Los Angeles (D.M.S.).
Akshay S DesaiCardiovascular Division, Brigham and Women's Hospital, Boston, MA (A.S.D.).
William T AbrahamDivision of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus (W.T.A.).
Robert C BourgeUniversity of Alabama at Birmingham (R.C.B.).
Nirav RavalFlorida Hospital Transplant Institute, Orlando (N.R.).
Lisa D RathmanCardiovascular Medicine Division, Lancaster General Hospital, PA (L.D.R.).
J Thomas HeywoodDivision of Cardiovascular Medicine, Scripps Green Hospital, La Jolla, CA (J.T.H.).
Rita A JermynDivision of Cardiology, St Francis Hospital, Roslyn, NY (R.A.J.).
Jamie PelzelCentracare Heart and Vascular Center, St Cloud, MN (J.P.).
Orvar T JonssonSanford Cardiovascular Institute, Sanford University of South Dakota Medical Center, Sioux Falls (O.T.J.).
Maria Rosa CostanzoAdvocate Heart Institute, Naperville, IL (M.R.C.).
John D HendersonAbbott, Sylmar, CA (J.D.H., M.-E.B., P.B.A.).
Marie-Elena BrettAbbott, Sylmar, CA (J.D.H., M.-E.B., P.B.A.).
Philip B AdamsonAbbott, Sylmar, CA (J.D.H., M.-E.B., P.B.A.).
Lynne W StevensonDivision of Advanced Heart Failure and Transplant Cardiology, Vanderbilt University Medical Center, Nashville, TN (L.W.S.).
CardioMEMS Post-Approval Study Investigators
Abbott (Sweden) · SEAdventHealth Orlando · USAdvocate Heart Institute · USBrigham and Women's Hospital · USJohn Abbott College · CALancaster General Hospital · USPhilips (Finland) · FISanford USD Medical Center · USScripps Green Hospital · USSt. Cloud Hospital · USSt. Francis Hospital · USThe Ohio State University Wexner Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Southern California · USVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmbulatory hemodynamic monitoring with an implantable pulmonary artery (PA) sensor is approved for patients with New York Heart Association Class III heart failure (HF) and a prior HF hospitalization (HFH) within 12 months. The objective of this study was to assess the efficacy and safety of PA pressure-guided therapy in routine clinical practice with special focus on subgroups defined by sex, race, and ejection fraction.

methodsThis multi-center, prospective, open-label, observational, single-arm trial of 1200 patients across 104 centers within the United States with New York Heart Association class III HF and a prior HFH within 12 months evaluated patients undergoing PA pressure sensor implantation between September 1, 2014, and October 11, 2017. The primary efficacy outcome was the difference between rates of adjudicated HFH 1 year after compared with the 1 year before sensor implantation. Safety end points were freedom from device- or system-related complications at 2 years and freedom from pressure sensor failure at 2 years.

resultsMean age for the population was 69 years, 37.7% were women, 17.2% were non-White, and 46.8% had preserved ejection fraction. During the year after sensor implantation, the mean rate of daily pressure transmission was 76±24% and PA pressures declined significantly. The rate of HFH was significantly lower at 1 year compared with the year before implantation (0.54 versus 1.25 events/patient-years, hazard ratio 0.43 [95% CI, 0.39-0.47],

conclusionsIn routine clinical practice as in clinical trials, PA pressure-guided therapy for HF was associated with lower PA pressures, lower rates of HFH and all-cause hospitalization, and low rates of adverse events across a broad range of patients with symptomatic HF and prior HFH. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02279888.

Indexed as

Blood Pressure Monitoring, AmbulatoryAgedFemaleHeart FailureHemodynamicsHospitalizationHumansMaleProspective StudiesPulmonary ArteryPulmonary Wedge PressureUnited Statesheart failurehemodynamicspopulationpressurepulmonary artery

Identifiers

PMID32757642
PMCPMC7434214
OpenAlexW3047723510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.